Goldman Sachs
DMK

Goldman Sachs’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Goldman Sachs’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-180
Closed -$7K – 6819
2022
Q1 		$7K Sell
180
-101
-36% -$4.33K ﹤0.01% 6503
2021
Q4 		$12K Buy
+281
New +$17.5K ﹤0.01% 6405
2021
Q3 		– Sell
-3,457
Closed -$266K – 6592
2021
Q2 		$266K Buy
+3,457
New +$211K ﹤0.01% 5590
2019
Q2 		– Sell
-863
Closed -$127K – 5405
2019
Q1 		$127K Buy
+863
New +$167K ﹤0.01% 4891
2018
Q2 		– Sell
-505
Closed -$124K – 6108
2018
Q1 		$124K Buy
505
+206
+69% +$54.1K ﹤0.01% 5204
2017
Q4 		$92K Buy
+299
New +$98.4K ﹤0.01% 5770
2015
Q4 		– Sell
-210
Closed -$57K – 7395
2015
Q3 		$57K Sell
210
-180
-46% -$50.1K ﹤0.01% 6744
2015
Q2 		$115K Hold
390
– – ﹤0.01% 6538
2015
Q1 		$107K Sell
390
-611
-61% -$264K ﹤0.01% 6402
2014
Q4 		$433K Sell
1,001
-201
-17% -$63.8K ﹤0.01% 5433
2014
Q3 		$394K Sell
1,202
-13
-1% -$3.81K ﹤0.01% 5491
2014
Q2 		$409K Buy
1,215
+274
+29% +$108K ﹤0.01% 5496
2014
Q1 		$419K Buy
+941
New +$427K ﹤0.01% 5434

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Goldman Sachs's DMK Position: Q2 2022 in Review

Goldman Sachs sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2022, closing a stake of 180 shares — an estimated $7K sold.

Goldman Sachs first reported a position in DMK in Q1 2014 and held it in 13 quarters. The position peaked at $433K in Q4 2014. 45 funds tracked by Wall St. Rank hold DMK as of Q2 2022.

  • Goldman Sachs reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2022 after selling out during the quarter.
  • Goldman Sachs sold 180 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2022, an estimated $7K.
  • Goldman Sachs first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q1 2014 and held it in 13 quarters.
  • Goldman Sachs's DMK Pharmaceuticals Corporation Common Stock position peaked at $433K in Q4 2014.
  • 45 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.